ClinicalTrials.gg
CompletedNCT06614803Updated Sep 26, 2024

Study of the Effects of Transcutaneous Auricular Vagus Nerve Stimulation Combined with Slow Breathing on Insomnia

An interventional study of Transcutaneous vagus nerve stimulation combined slow breathing and Transcutaneous vagus nerve stimulation in Insomnia, sponsored by Xidian University. Completed at 1 site in China. Open to participants aged 18 Years to 28 Years. Per ClinicalTrials.gov, last updated 2024-09-26.

Sponsored by Xidian University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jan 2024, registered Sep 2024).
Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years to 28 Years
Sex
All
01

Study summary

The study recruited college students with insomnia disorders and applied transcutaneous auricular vagus nerve stimulation(taVNS) combined with slow breathing. The main aims of the study are: 1) to explore the role of this novel and effective physical therapy technique of taVNS combined with slow breathing in regulating insomnia; 2) to investigate the relationship between the synergistic effect of taVNS and slow breathing on interoceptive indicators and their therapeutic effects.

Read the detailed description

This study conducted a randomized controlled clinical trial with an intention to enroll 80 insomnia participants. Participants were randomly assigned in a 1:1:1:1 ratio to four groups:1)taVNS combined with slow breathing group;2)taVNS with normal breathing group;3)slow breathing with sham taVNS group;4)normal breathing with sham taVNS group.The study included a one-week baseline period, a two-week treatment period, and a two-week follow-up period. During the 2-week treatment period, 20 minutes of continuous treatment was performed every evening. The stimulation parameters were set to 20Hz, 200μs, 5s ON-5s OFF and a burst frequency of 2000Hz. For taVNS combined with slow breathing group,after preparing the skin, electrodes were attached to the tragus and cymba conchae of the left ear,and under the guidance of the device\'s video, the participants were instructed to perform six slow and relaxed breaths per minute (0.1Hz), while the device delivered stimulation during the 5 seconds of exhalation.For taVNS with normal breathing group,without video guidance on the device, the participants breathed freely while receiving normal taVNS intervention.For slow breathing with sham taVNS group,the participants followed the video instructions to perform slow breathing while wearing the stimulation electrodes, but the device only outputted stimulation for one minute.For normal breathing with sham taVNS group,the device outputted stimulation for only one minute, and the participants breathed normally. EEG and ECG data were collected before and after the 2-week treatment, and scale data were collected before and after the treatment as well as at the end of follow-up. Sleep diaries were recorded throughout the 5-week period.

02

Conditions studied

  • Insomnia

Keywords

  • Insomnia
  • Interoception
  • Transcutaneous Auricular Vagus Nerve Stimulation
  • Slow Breathing
03

In context

Sleep Initiation and Maintenance Disorders

2,722 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 726 are open to participants now.

This study's enrollment of 80 is above the median of 68 across 2,350 interventional studies indexed under Sleep Initiation and Maintenance Disorders.

Browse Sleep Initiation and Maintenance Disorders studies →

Lead sponsor

Xidian University is the lead sponsor of 14 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 28 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age over 18 years;
  2. Meet the definition of insomnia in the 5th Edition (DSM-V);
  3. Has not received any psychotropic drug treatment;
  4. PSQI(Pittsburgh Sleep Quality Index) score>7;
  5. ISI(Insomnia Severity Index) score≥11;
  6. Signed form;
  7. Ability and willingness to comply with the study requirements.

Exclusion criteria

Exclusion Criteria:

  1. There are learning or working hours that affect the circadian rhythm;
  2. There is abuse of alcohol, nicotine, or other substances;
  3. Pregnancy, breastfeeding, or plans to become pregnant;
  4. Damage or allergy to the selected stimulation site;
  5. Clinically diagnosed mental disorders and other medical conditions;
  6. Currently taking stimulant, hormone, or other medications that may cause insomnia and are not suitable for discontinuation.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
80 participants (actual)

Study arms

  • Active comparator
    taVNS combined with slow breathing

    For taVNS combined with slow breathing group,after preparing the skin with an alcohol pad, electrodes were attached to the tragus and cymba conchae of the left ear,and under the guidance of the device's video, the participants were instructed to perform six slow and relaxed breaths per minute (0.1Hz), while the built-in parameters of the device delivered stimulation during the 5 seconds of exhalation.The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs, and a burst frequency of 2000Hz, 5s ON-5s OFF;stimulation time:20min.

    Device: Transcutaneous vagus nerve stimulation combined slow breathing

  • Active comparator
    taVNS with normal breathing

    For taVNS with normal breathing group,without video guidance on the stimulation device, the participants breathed freely while receiving normal tVNS intervention.Electrodes were attached to the tragus and cymba conchae of the left ear. The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs, 5s ON-5s OFF, and a burst frequency of 2000Hz, ;stimulation time:20min.

    Device: Transcutaneous vagus nerve stimulation

  • Active comparator
    slow breathing with sham taVNS

    For slow breathing with sham taVNS group,the participants followed the video instructions to perform slow breathing while wearing the stimulation electrodes, but the device only outputted stimulation for one minute and then stopped.

    Device: Transcutaneous vagus nerve stimulation combined slow breathing

  • Sham comparator
    normal breathing with sham taVNS

    For normal breathing with sham taVNS group,the device were set to output stimulation for only one minute and then stop, and the participants breathed normally

    Device: Transcutaneous vagus nerve stimulation

Interventions

  • DeviceTranscutaneous vagus nerve stimulation combined slow breathing

    The stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear,the screen of the device displays slow breathing guidance video at 0.1Hz, while the device delivered stimulation during the 5 seconds of exhalation.

  • DeviceTranscutaneous vagus nerve stimulation

    Without slow breathing guidance video on the stimulation device,the stimulation parameters were set to a burst pulse wave with a frequency of 20Hz, 200μs,5s ON-5s OFF,and a burst frequency of 2000Hz. Electrodes were attached to the tragus and cymba conchae of the left ear

06

What researchers measure

Primary outcomes

  1. Sleep diary indicators after two weeks of treatment

    Sleep latency, sleep efficiency, wake time after sleep onset, number of wake times after sleep onset, and total sleep time were used as the primary outcome measure in the sleep diary.

    Time frame: Sleep diaries were collected daily for five weeks, but changes in sleep diary data were assessed after one week baseline, two weeks of treatment, and two weeks of follow-up.

Secondary outcomes

  1. Changes in heart rate variability

    Heart rate variability(HRV) were analyzed to evaluate the mean peak interval (MeanRR) of the RR and three commonly used measures of autonomic nervous function: the root mean square sum of the difference between adjacent normal heartbeat intervals (RMSSD), the percentage of adjacent NN differences greater than 50ms in the total number of sinus heart beats (PNN 50%), and high frequency power (aHF).

    Time frame: Heart rate variability will be assessed twice within five weeks:at baseline,and after two weeks of treatment.

  2. Changes in heartbeat evoked potential

    Heartbeat evoked potential(HEP) is the electrical activity of the brain at a specific moment in the heart cycle, which is synchronized with the R wave of the heart's electrical signals and can be measured by recording the electrical activity of the brain at a specific point in time within the heartbeat cycle. HEP represents an electrophysiological marker of cortical processing of incoming cardiovascular information.

    Time frame: Heartbeat evoked potential will be assessed twice within five weeks:at baseline,and after two weeks of treatment.

  3. Changes in ISI scores

    The Insomnia Severity Index (ISI) is utilized to assess the severity of insomnia and its impact on physical health, daily function, and quality of life. This scale includes seven items, with a total scoring range from 0 to 28. Higher scores denote more severe insomnia. The change in ISI score will be determined by subtracting the baseline score from the score at each subsequent time point.

    Time frame: ISI will be assessed three times within five weeks: at baseline, after two weeks of treatment, and two weeks of follow-up.

  4. Changes in PSQI scores

    The Pittsburgh Sleep Quality Index(PSQI) assessed the sleep quality of the participants in the last 1 month, which was composed of 19 self-rated items and 5 other rated items, in which the 19th self-rated items and 5 other rated items did not participate in the score. The 18 self-rated entries that participate in the scoring can be combined into seven sections. They were: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disorders, hypnotic drug use and daytime dysfunction. Each part is scored from 0 to 3, and the cumulative score of each part is divided into PSQI total score, ranging from 0 to 21, and the higher the score, the worse the sleep quality

    Time frame: PSQI will be assessed three times within five weeks: at baseline, after two weeks of treatment, and two weeks of follow-up.

  5. Change in PHQ-9 scores

    The Patient Health Questionnaire-9 (PHQ-9) encompasses nine items, each representing a different facet of depressive symptoms. The total score ranges from 0 to 27, with higher scores indicating more severe depressive symptoms. The change in PHQ-9 score will be determined by subtracting the baseline score from the score at each subsequent time point.

    Time frame: PHQ-9 will be assessed three times within five weeks: at baseline, after two weeks of treatment, and two weeks of follow-up.

  6. Change in GAD-7 scores

    The Generalized Anxiety Disorder Scale (GAD-7) is used to assess the emotional state of patients. The Generalized Anxiety Disorder Scale (GAD-7) comprises seven items, with a total possible score ranging from 0 to 21. An elevated score suggests a more pronounced level of anxiety. The change in GAD-7 score will be determined by subtracting the baseline score from the score at each subsequent time point.

    Time frame: GAD-7 will be assessed three times within five weeks: at baseline, after two weeks of treatment, and two weeks of follow-up.

  7. Change in FFS scores

    The Flinders Fatigue Scale(FFS) consists of seven entries that measure various fatigue characteristics (e.g., frequency, severity) experienced during the past two weeks. Six items were presented in Likert form, with responses ranging from 0(not at all) to 4(very serious). The total score is calculated by the sum of all the items. The total score of the scale ranges from 0 to 31 points, and the higher the score, the more serious the fatigue degree of patients.

    Time frame: FFS will be assessed three times within five weeks: at baseline, after two weeks of treatment, and two weeks of follow-up.

07

Study locations

1 site
  • Xidian University
    Xi'an, Shaanxi, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jul 2024, 6 months.

Of 1,207 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's 6 months is below that.

Counting every sponsor, half of 1,285 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 26, 2024
StartActual
Jan 1, 2024
Primary completionActual
Jul 14, 2024
CompletionActual
Jul 31, 2024
Last update
Sep 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06614803
Lead sponsor
Xidian University
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Jan 1, 2024
Primary completion
Jul 14, 2024
Completion
Jul 31, 2024
Last update
Sep 26, 2024

Study contacts

Qin Wei, Phd
principal investigator · Xidian University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion